Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Bardet, Valérie; Wagner-Ballon, Orianne; Guy, Julien; Morvan, Céline; Debord, Camille; Trimoreau, Franck; Benayoun, Emmanuel; Chapuis, Nicolas; Freynet, Nicolas; Rossi, Cédric; Mathis, Stéphanie; Gourin, Marie-Pierre; Toma, Andréa; Béné, Marie C.; Feuillard, Jean; Guérin, Estelle

doi:10.3324/haematol.2014.112755

Cited by 31 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe that setting up the “Ogata score” is technically easy, time‐ and cost‐efficient, making it suitable for general use in LA laboratories. Additionally, its reproducibility has already been demonstrated by different groups …”

Section: Discussionmentioning

confidence: 80%

“…Hence, many research groups are working on its improvement. Bardet et al have reported that the addition of two new variables (CD7 aberrant expression on myeloid progenitors and CD56 on monocytes) improve the score sensitivity. Recently, Ogata et al have also reported that adding the CD33 expression on CD34+ cells as a fifth parameter (called granulocyte/CD34 cell CD33 ratio) to the classic four parameters improves it sensitivity.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, its reproducibility has already been demonstrated by different groups. 9,23,30,31 One important drawback of the "Ogata score" is that the sen- 23 Another study evaluating the combination of the "Ogata score" with the erythroid parameters recommended by IMDSFlow working group (CD36 and CD71 distribution, CD36 expression on erythroid lineage and CD117+ erythroid precursors) showed an improved diagnostic power (sensitivity of 86% and specificity of 95%). 33 Furthermore, integrating the "Ogata score," "Wells FCSS," and the erythroid parameters recommended by IMDSFlow working group, into the so-called Integrated Flow Cytometry score (iFCs), showed 80% sensitivity and 95% specificity.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The “Ogata score” is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low‐risk MDS. We aimed to study the feasibility and the utility of the “Ogata score” for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. “Ogata score” was calculated. Results The sensitivity of “Ogata score” was 75.6% (95% CI, 66.8‐81.3), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 95.6% (95% CI, 88.5‐98.3), and NPV was 65.4% (95% CI, 49.1‐71.9). In low/intermediate‐1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2‐78.2), specificity was 91.2% (CI‐95%, 79.7‐96.7), PPV was 94.2% (95% CI, 86.4‐97.8), and NPV was 62.1% (95% CI, 53.0‐78.7). In the group of patients “without MDS specific markers” (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI‐95%, 55.8‐76.0), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 92.3% (95% CI, 82.2‐97.1), and NPV was 63.5% (95% CI, 51.9‐73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della‐Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…To improve the four-parameter diagnostic score, Bardet and colleagues advised the addition of CD7 (on myeloid progenitors) and CD56 (on monocytes) to the diagnostic score. 28 Specificity of this adjusted score was 87%; however, the sensitivity was low (66%). Here, the addition of selected erythroid markers might improve the sensitivity of FC.…”

Section: Discussionmentioning

confidence: 99%

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

et al. 2016

View full text Add to dashboard Cite

“…It is well established that the sensitivity of this and other scoring systems is highest for the high-risk groups. 18…”

Section: Limitations Of This Studymentioning

confidence: 99%

Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome

Matzen

Raaschou‐Jensen

Kallenbach

2018

Health Science Reports

View full text Add to dashboard Cite

Background and AimsCompiling evidence has emerged for the relevance of flow cytometric assessment as a valuable part of the diagnostic work‐up of myelodysplastic syndrome (MDS). This study aimed at evaluating the implementation of a simple flow cytometric scoring system (FCSS), the Ogata score, in a routine diagnostic laboratory.MethodsA total of 35 patient samples with a clinical suspicion of MDS were retrospectively assessed using the FCSS. The accuracy of the FCSS was evaluated on the basis of the final diagnoses of the patients.ResultsThe final diagnoses included 17 MDS, 4 other myeloid cancers, and 14 reactive changes. Thirty‐two of 35 (91%) were correctly scored by the FCSS. All 3 incorrect scores were from samples classified as “other myeloid cancers.” Of the initial pathological evaluation of the bone marrows, 20% were inconclusive or incorrect. All inconclusive samples were correctly scored using the FCSS.ConclusionThe FCSS evaluated here has high accuracy and low complexity. Cases with inconclusive pathological evaluation will especially potentially benefit from adding the Ogata score to the diagnostic work‐up. The system will be feasible to implement in most flow cytometry laboratories without the need for supplemental antibody panels. It should be emphasized that the FCSS, in our hands, provided poor discrimination between MDS and other myeloid clonal diseases.

show abstract

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Abstract: ABSTRACT

Cited by 31 publications

References 26 publications

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome

Contact Info

Product

Resources

About